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Background: Textbook outcome (TO) is a multidimensional measure for
quality assurance, reflecting the ‘‘ideal’’ surgical outcome.
Methods: Post-hoc analysis of patients who underwent pancreatoduodenec-
tomy (PD) or distal pancreatectomy (DP) for all indications between 2014 and
2017, queried from the nationwide prospective Dutch Pancreatic Cancer
Audit. An international survey was conducted among 24 experts from 10
countries to reach consensus on the requirements for TO in pancreatic surgery.
Univariable and multivariable logistic regression was performed to identify
TO predictors. Between-hospital variation in TO rates was compared using
observed-versus-expected rates.
Results: Based on the survey (92% response rate), TO was defined by the
absence of postoperative pancreatic fistula, bile leak, postpancreatectomy
hemorrhage (all ISGPS grade B/C), severe complications (Clavien–Dindo
III), readmission, and in-hospital mortality. Overall, 3341 patients were
included (2633 (79%) PD and 708 (21%) DP) of whom 60.3% achieved TO;
58.3% for PD and 67.4% for DP. On multivariable analysis, ASA class 3
predicted a worse TO rate after PD (ASA 3 OR 0.59 [0.44–0.80]), whereas a
dilated pancreatic duct (>3mm) and pancreatic ductal adenocarcinoma
(PDAC) were associated with a better TO rate (OR 2.22 [2.05–3.57] and
OR 1.36 [1.14–1.63], respectively). For DP, female sex and the absence of
neoadjuvant therapy predicted better TO rates (OR 1.38 [1.01–1.90] and OR
2.53 [1.20–5.31], respectively). When comparing institutions, the observed-
versus-expected rate for achieving TO varied from 0.71 to 1.46 per hospital
after casemix-adjustment.
Conclusions: TO is a novel quality measure in pancreatic surgery. TO varies
considerably between pancreatic centers, demonstrating the potential benefit
of quality assurance programs.
Keywords: auditing, outcomes, pancreatic surgery, practice variation,
surgery, textbook outcome
(Ann Surg 2020;271:155–162)
C linical auditing and quality improvement is increasingly impor-tant in the field of surgery.1 This process is also driven by
hospitals, governmental institutions, and other providers as they
increasingly demand transparency to monitor and improve clinical
outcomes.2 In the United States and Europe, several prospective
surgical registries have been established to support this goal.3–6 In
the Netherlands, clinical auditing designed for quality improvement
purposes and reduction of unwanted variation in clinical practice has
been implemented for many surgical procedures.7 One of these audits
is the Dutch Pancreatic Cancer Audit (DPCA), a mandatory nation-
wide prospective registry for pancreatic surgery.6
Monitoring and comparing quality of specific procedures,
such as pancreatic resections, requires a broad judgement which
may be difficult to obtain.8,9 Although different outcome parameters
are generally related to each other, a composite outcome measure
based on a variety of short-term outcomes might offer a better, and
potentially more stable reflection of overall quality than single-
outcome indicators like mortality, morbidity, or readmission
rates.10,11 Textbook Outcome (TO) is such a composite outcome,
which attempts to cover the entire surgical process in a single
indicator. TO, reflecting the ideal surgical outcome, is realized when
all prespecified requirements of TO are fulfilled according to an all-
or-none principle.12 TO has been defined for several surgical pro-
cedures, including abdominal aneurysm surgery, oesophageal/gastric
surgery, and colorectal surgery.13–15 The requirements of TO would
ideally be disease-specific and surgery-related parameters, covering
all important aspects of a patients’ postoperative course with the
possibility for ‘‘case-mix correction’’ to account for variance in
patient populations between centers. The definition of surgical
quality and what constitutes TO, however, is arbitrary, subject to
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cultural differences and might even change over time.16 Neverthe-
less, previous studies in other surgical fields demonstrated that TO
was a feasible and useful parameter for comparison of quality
between institutions, also showing correlation with improved
long-term outcomes after cancer surgery.13–15,17,18
This study proposes a TO definition for pancreatic surgery,
based on the opinion of international experts, and assesses predictors
and associations with TO in a nationwide surgical audit.
METHODS
Study Design and Data Collection
Patients who underwent pancreatoduodenectomy (PD) or
distal pancreatectomy (DP) for all indications between
January 2014 and December 2017 in the Netherlands were eligible
for this study. Data were obtained from the prospectively maintained,
mandatory, nationwide DPCA.6 The DPCA covers all pancreatic
resections for both malignant and benign/premalignant tumors in the
Netherlands since January 2014. A previously published internal
audit of the DPCA demonstrated a high degree of accuracy (97.2%)
and case ascertainment (93.0%).6 Patients with missing data on 1 or
more of the requirements for TO according to the survey
were excluded.
Baseline characteristics, pathological parameters, and short-
term outcomes up until 30 days postdischarge are collected by each
institution and are centrally archived in a nationwide database. Study
proposals and data requests using the DPCA are reviewed by a
scientific board of the Dutch Pancreatic Cancer Group, after which
the data, in case of unanimous approval, are anonymized and
provided for research purposes. As anonymized data was used, no
ethical approval was required by the Institutional Review Boards.
Regarding pathology definitions, any type of ductal adeno-
carcinoma (pancreatic, ampullary, distal bile duct, or duodenal), and
neuro-endocrine tumors grade II and III of the pancreas were
classified as malignant.19 Noninvasive IPMN, neuroendocrine
tumors grade I, and solid pseudopapillary neoplasms were classified
as premalignant/benign.
Survey on the Definition of Textbook Outcome
In order to reach international consensus on all requirements
for TO, a survey was conducted among 24 internationally recog-
nized experts from 21 institutions, in 10 different countries spanning
4 continents. Experts were systematically identified by contacting
the senior authors of large single-center studies (>1000 PDs) or
studies on quality improvement in (pancreatic) surgery. The survey
consisted of 17 items, which were each rated on a 5-point Likert
scale whether the respondent agreed on that particular item to be a
requirement for TO. An agreement rate of >80% per item was
considered as consensus and resulted in the item being included in
the definition of TO. The survey outcome and definition of TO are
presented in the Results section. The international experts are
presented in the supplementary table S2, http://links.lww.com/
SLA/B689.
Statistical Analysis
Continuous variables were presented as median with
interquartile range (IQR), or dichotomized on a clinically rele-
vant cut-off value. Categorical variables were presented as
frequencies and proportions, or in some cases as proportions
only to omit large numbers. TO was determined for each patient,
according to the selected items through the survey. TO was
achieved when a patients’ admission met all TO requirements.
TO rates were compared between groups using the
Chi-square test.
Multiple imputation was used to impute missing baseline and
treatment variables by creating 5 datasets, using the mice package in
R (predictive mean matching). In order to assess between-hospital
variations in TO rate, casemix-adjustment was performed with
logistic regression using relevant baseline variables which may have
played a role in patient selection (sex, age [continuous], BMI
[continuous], preoperative low serum albumin [below 3.5 g/dL],
WHO performance status [0, 1, 2, or 3], pancreatic texture [soft
or hard], and pathology [pancreatic cancer or other]). Based on the
covariates (ie, casemix) a predicted probability to achieve TO was
estimated, with subsequently observed-versus-expected (O/E) TO
rates being calculated per hospital. O/E rates higher than 1 represent
better TO rates than predicted and O/E rates lower than 1 worse than
predicted, based on the casemix for that specific hospital. O/E rates
were presented in a funnel plot to visualize volume–outcome
relationships. Additionally, multivariable logistic regression was
performed to identify clinicopathological predictors of TO. Variables
were excluded through backward selection until only statistically
significant variables were selected in the final model. Two-sided P
values of less than 0.05 were considered statistically significant and
odds ratios (OR) and their 95% confidence intervals (CI) were
reported. All analyses were performed using R version 3.4.3
(cran.r-project.org).
RESULTS
Survey Outcome
Based on the survey (92% response rate), 6 out of the 17 items
were selected as requirements for TO with an agreement rate of
>80%. TO was defined as the absence of postoperative pancreatic
fistula (POPF), bile leak, postpancreatectomy hemorrhage (all grade
B/C according to ISGPS or ISGLS),20–22 severe complications
(Clavien–Dindo grade III),23 readmission within 30 days after
discharge, and in-hospital or 30-day mortality. For the current study
only in-hospital mortality was available in the DPCA, which was
used instead in our analyses. Furthermore, the items regarding
complications rated as Clavien–Dindo grade III and a postopera-
tive reintervention (surgical, endoscopic, or radiological) were com-
bined in 1 item, due to the same nature of these items. Since previous
TO publications also included prolonged length of stay (LOS) as
requirement, additional analyses were performed using an extended
definition (TOþLOS) with prolonged LOS defined as>14 days. The
various agreement rates of the survey are presented in the supple-
mentary tables S1 and S2, http://links.lww.com/SLA/B689.
Baseline Characteristics
In total, 3520 patients met the inclusion criteria. Of those, 179
(5.1%) patients were excluded for missing data on 1 or more
requirements of TO. The final cohort consisted of 3341 patients,
of which 2633 (78.8%) patients underwent PD and 708 (21.2%)
patients underwent DP. The median age was 67 (IQR 58–74) years,
54.3% of the patients were male. The majority of patients had an
American Society of Anesthesiologists (ASA) score of 1 or 2
(77.8%), a WHO performance status of 0 or 1 (89.0%), a BMI lower
than 30 kg/m2 (86.6%) and underwent surgery for a malignancy
(76.6%). In-hospital mortality was 3.2%; 3.7% for PD and 1.5% for
DP, respectively (P ¼ 0.006). All baseline characteristics are pre-
sented in Table 1.
Textbook Outcome Rates
The overall proportion of patients who achieved TO was
60.3%. TO was realized in 58.3% of patients after PD versus
67.4% of patients after DP (P < 0.001). Among the different items
of TO, a complication of Clavien–Dindo grade III (requiring
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endoscopic, radiologic, or surgical reintervention) occurred most
often with a rate of 30.4% and 19.6% for patients who underwent PD
and DP, respectively (P< 0.001). The rates of the 6 TO items and the
cumulative percentages are displayed in Figure 1. Among patients
who underwent PD, patients with TO had lower ASA scores (P ¼
0.006) and more often a dilated pancreatic duct (P < 0.001) than
patients who did not achieve TO. Among patients who underwent DP,
patients with TO less often received neoadjuvant therapy (P¼ 0.02).
Between-hospital Variation
During 2014 to 2017, 20 centers performed pancreatic surgery
in the Netherlands, with 18 centers performing  20 PDs annually
and, of those, 5 centers performing  40 PDs annually. The median
number of annually performed procedures was 33 (IQR 27–39) for
PD and 8 (IQR 5–10) for DP per hospital. Unadjusted TO rates
varied considerably between hospitals, with a range of 35.2% to
87.7% for PD and 47.6% to 91.2% for DP. When adjusted for
casemix, the O/R rates ranged from 0.71 to 1.46 per hospital
for all pancreatic surgeries, with O/R rates ranging from 0.61 to
1.56 for PD and from 0.71 to 1.32 for DP. There was no evident
correlation between procedure volume and TO rate, as presented in
Figure 2A and B.
Multivariable Analysis
On multivariable analysis, only class ASA 3 predicted a worse
TO rate after PD (OR 0.62 [0.46–0.83]), whereas a dilated pancreatic
duct (>3mm) and pancreatic ductal adenocarcinoma (PDAC) were
associated with a better TO rate (OR 2.22 [2.05–3.57] and OR 1.36
[1.14–1.63], respectively). For DP, female sex and the absence of
neoadjuvant therapy were associated with a better TO rate (OR 1.38
[1.01–1.90] and OR 2.53 [1.20–5.31], respectively). Results of
univariable and multivariable analysis are presented for PD and
DP in Tables 2 and 3, respectively.
Additional Analyses Using the Extended Definition
(TORLOS)
When applying the extended definition, TOþLOS rates
decreased from 58.3 to 47.5% for PD and from 67.4 to 63.3% for
DP. When assessing factors associated with TOþLOS on multivari-
ate analysis, age>75 years was identified as additional risk factor for
a lower TOþLOS rate after PD (OR 0.78 [95% CI 0.64–0.96]).
Among patients who underwent DP, vascular resection was identified
as additional predictor for TOþLOS (OR 0.34 [95% CI 0.14–0.79]).
The rest of the results did not change significantly with the
extended definition.
DISCUSSION
This study proposed a novel consensus-based definition of TO
in pancreatic surgery (absence of all of the following parameters:
postoperative pancreatic fistula, bile leak, postpancreatectomy hem-
orrhage, Clavien–Dindo III complications, readmission and in-
TABLE 1. Baseline Characteristics by Type of Surgery
Pancreatoduodenectomy Distal Pancreatectomy
Total cohort Textbook Outcome Textbook Outcome
(n ¼ 3341) Yes (n ¼ 1536) No (n ¼ 1097) P value Yes (n ¼ 477) No (n ¼ 231) P value
Clinical parameters
Elderly patients (>75 yrs), % 17.5 18.9 19.0 0.99 13.5 9.5 0.13
Male, % 54.3 44.3 57.5 0.35 43.8 51.5 0.05
ASA score, %
ASA I 15.5 14.3 13.7 0.006 19.6 21.8 0.62
ASA II 62.3 65.6 60.6 60.2 54.2
ASA III 21.8 20.0 25.3 19.6 22.3
ASA IV 0.4 0.1 0.5 0.6 1.7
BMI 30 kg/m2, % 13.2 10.7 13.1 0.08 18.6 22.6 0.23
WHO performance status, %
0-1 89.0 88.7 89.3 0.62 85.9 88.5 0.48
 2 11.0 11.3 10.7 14.1 11.5
Dilated pancreatic duct (>3 mm), % 48.6 65.7 42.6 <0.001 30.2 21.1 0.19
Neoadjuvant therapy, % 3.8 3.5 3.9 0.55 3.0 7.0 0.02
Malignant diagnosis, % 76.6 84.2 82.8 0.35 49.5 54.4 0.24
Year of surgery, %
2014 24.3 24.2 25.7 0.31 22.6 22.5 0.97
2015 24.3 25.3 24.5 21.8 21.2
2016 25.1 24.1 26.6 26.0 27.3
2017 26.3 26.4 24.2 29.6 29.0
Operative parameters
Minimally invasive, % 20.8 12.3 16.0 0.007 54.7 50.7 0.36
Vascular resection, % 12.4 15.9 13.3 0.07 2.8 5.4 0.10
Textbook Outcome items TO No TO TO No TO
In-hospital mortality 3.2 96.3 3.7 98.5 1.5
POPF grade B/C 14.5 86.4 13.6 82.1 17.9
PPH grade B/C 7.3 91.9 8.1 95.9 4.1
Bile leak grade B/C 4.2 94.9 5.1 99.2 0.8
Complication CD  III 28.1 69.6 30.4 80.4 19.6
Readmission 16.7 83.1 16.9 84.3 15.7
Textbook outcome percentages are displayed per item, TO versus no TO.
Values are percentages. ASA indicates American Association of Anesthesiologists; BMI, body mass index; PPPD, pylorus-preserving pancreatoduodenectomy; WHO, World
Health Organization.
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hospital mortality) as agreed by an international survey. The nation-
wide analysis demonstrated its feasibility and utility to assess clinical
outcome of pancreatic surgery with 60.3% TO. On multivariable
analysis, a higher ASA class was predictive for a worse TO rate after
PD, whereas a dilated pancreatic duct (>3mm) and PDAC were
associated with an improved TO rate. For DP, female sex and the
absence of neoadjuvant therapy were independently associated with
improved TO rates. There was considerable variation in TO rates
between pancreatic centers, supporting the need and potential for
quality assurance programs. The present study demonstrated that
only limited preoperative available parameters were predictive for
TO. On a nationwide basis, however, TO might be a powerful
outcome measure to be evaluated as an instrument for comparing
quality of surgical practice between different institutions and
national registries.
The multidimensional parameter TO is a relatively new
concept which was found useful in other fields of surgery.13–
15,17,18 Our definition of TO was established by an international
survey, conducted among experts in quality improvement in (pan-
creatic) surgery. Out of 17 items, absence of 6 complications was
considered to reflect the ideal outcome after pancreatic surgery.
Prolonged hospital stay was initially not included in these 6 require-
ments. Although hospital readmissions are generally expensive, at
times avoidable and in some countries even a tool for
penalization,24,25 many cultural differences exist worldwide regard-
ing hospital stay. For instance, in southern Europe and in Japan
patients are often not discharged until fully recovered, which may
take 3 to 4 weeks. The external validity of TO may therefore actually
benefit by not including prolonged hospital stay as a complication.
Recently, another study investigated TO among Medicare patients
who underwent hepatopancreatic surgery.26 This study included
length of stay as one of the requirements for TO (>50th percentile
for each procedure). This study also combined distal pancreatectomy
and pancreateoduodenectomy, impeding the generalizability and
translatability of the results to daily practice. The variation in overall
TO rates in this study [range 11.1–69.6%] seems fairly in line with
our findings.26
Compared with the TO definition in colorectal and oesopha-
gogastric surgery, the proposed TO definition for pancreatic surgery
does not contain pathology-related variables.14,15 This decision was
taken after consultation with several pancreatic pathologists for 2
reasons. First, pancreatic surgery includes a considerable proportion
of benign and premalignant lesions (23.4% in the present study).
With these patients in mind, incorporating resection margin status
and lymph node yield would further complicate the definition of TO.
Second, the R1 rate in pancreatic surgery does not necessarily reflect
surgical technique but rather the extent of pathological assessment
and the disease itself.27,28 For example, tumor invasion in the anterior
FIGURE 1. Textbook Outcome percentages (per item and cumulative) for pancreatoduodenectomy and distal pancreatectomy.
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FIGURE 2. A, Funnel plot of between-hospital variation in Textbook Outcome after pancreatoduodenectomy during 2014–2017.
O/E ratio: observed number of Textbook Outcome patients divided by expected^ number of Textbook Outcome patients. O¼ E:
the observed number equals the expected^ number of Textbook Outcome patients. ^Expected based on population characteristics
in t. B, Funnel-plot of between-hospital variation in Textbook Outcome after distal pancreatectomy during 2014–2017. O/E ratio:
observed number of Textbook Outcome patients divided by expected^ number of Textbook Outcome patients. O ¼ E: the
observed number equals the expected^ number of Textbook Outcome patients. ^Expected based on population characteristics in t.
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margin results in an R1 resection, which is not under influence of the
surgeon and more a sign of advanced disease. Therefore, only
surgical and no pathological variables were included in our TO
definition for pancreatic surgery.
Other variables related to the quality of pancreatic surgery
could also be considered, such as prolonged operative time, intra-
operative blood loss, or postoperative transfusions. Although these
variables have been found to be associated with worse outcomes,29,30
it might be difficult to obtain accurate measurements and these
parameters might not necessarily imply lower surgical quality but
rather more difficult cases. More importantly, the experts of the TO
design panel decided not to include intraoperative parameters in the
survey round, so eventually only items related to postoperative
clinical outcome were considered most relevant to the patient.
In the literature, several factors have been identified as
predictors for postoperative morbidity and mortality after PD,
including a higher ASA score, a small pancreatic duct, a soft
pancreas, high-risk pathology (nonmalignant), and excessive blood
loss.31–33 Our results showed that patients with a higher ASA class, a
smaller pancreatic duct (<3mm) and a diagnosis other than PDAC
were independently associated with lower TO rates after PD, which
are in line with previously published findings. For DP, similar risk
factors have been shown to be associated with POPF after DP,
including a soft pancreas, neuroendocrine or nonmalignant pathol-
ogy, a higher BMI, blood transfusion, and longer operative time.34,35
Remarkably, our findings demonstrate superior TO rates in female
patients and those who did not receive neoadjuvant treatment.
Perhaps, patients who were selected for neoadjuvant therapy were
more likely to undergo extensive surgery with multivisceral resection
due to more advanced tumors. Not enough covariates (ie, potential
confounders) were available to adjust for this relationship and to
warrant causal inference.
Our study also identified a considerable variability of TO rates
between pancreatic centers, ranging from 35.2 to 87.7% for PD and
47.6 to 91.2% for DP. Although subject to sampling error and
potentially selection bias, especially for lower volume centers, this
variability would seem undesirable. Quality assurance programs
could improve this variation. Casemix-adjustment did not reduce
much of the differences in TO rates between institutions. This
minimal effect of casemix-adjustment suggests that patient selection
played a minor role in the observed differences between centers. In
addition to assessing predictors or factors associated with TO, the key
in assessing surgical quality through parameters such as TO is mainly
in revealing practice variation and potentially identify institutions
that might benefit most from quality improvement. Besides improv-
ing treatments at already excellent institutions, quality improvement
programs might help to improve overall and nationwide perfor-
mance. In evaluating surgical quality in a broad perspective, TO
demonstrates to be a useful indicator.
These results should be interpreted with several limitations in
mind. First, in a nationwide registry not all parameters are recorded, or
not recorded with sufficient detail. This could preclude in-depth study
of relationships and adjustment for all potential confounders. Second,
there remains significant variation in postoperative strategy between
TABLE 2. Multivariate Analysis of Parameters Associated With Textbook Outcome After Pancreatoduodenectomy
Univariable Multivariable
Clinical Parameters OR (95% CI) P Value OR (95% CI) P Value
Age
 75 yrs Ref
> 75 yrs 0.99 (0.82–1.22) 0.99
Sex
Male Ref
Female 1.08 (0.92–1.26) 0.35
ASA score
ASA I Ref Ref
ASA II 1.03 (0.82–1.30) 0.78 0.92 (0.71–1.18) 0.36
ASA III 0.76 (0.58–0.98) 0.04 0.62 (0.46–0.83) <0.001
ASA IV 0.27 (0.05–1.43) 0.12 0.19 (0.04–1.04) 0.06
BMI
<30 kg/m2 1.25 (0.98–1.60) 0.08
30 kg/m2 Ref
Performance status
WHO 0–1 Ref
WHO  2 1.07 (0.82–1.38) 0.62
Dilated pancreatic duct
 3 mm Ref Ref
> 3 mm 2.58 (1.97–3.36) <0.001 2.22 (1.77–2.79) <0.001
Neoadjuvant therapy
Yes Ref
No 1.13 (0.75–1.71) 0.55
Histological diagnosis
PDAC 1.72 (1.47–2.02) 1.36 (1.14–1.63)
Other Ref <0.001 Ref <0.001
Operative parameters
Vascular resection
Yes 1.23 (0.99–1.54) 0.07
No Ref
ASA indicates American Association of Anesthesiologists; BMI, body mass index; CI, confidence interval; OR, odds ratio; PDAC, pancreatic ductal adenocarcinoma;WHO,World
Health Organization.
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institutions, that is, percutaneous catheter drainage for small amounts
of peripancreatic fluid after pancreatoduodenectomy or endoscopic
placement of a nasojejunal feeding tube (both considered as a Clav-
ien–Dindo grade III complication and thus, consequently, absence of
TO).23 However, adequate complication management also reflects
hospital experience and expertise, which consequently has its impact
on clinical outcome.36 Third, it should be noted that TO does not make
a distinction in terms of severity. Patients with a Clavien–Dindo grade
III complication and otherwise uncomplicated course have the same
score (no TO) as a postoperative death. Fourth, TO is an important
outcome parameter as experienced by involved surgeon and not by
involved patients. In this sense patient recorded outcomemeasures (ie,
discharge to home or revalidation clinic, ability to work) will gain
significance in future quality programs. Furthermore, it should be
addressed that if TO would be implemented as a part of a nationwide
audit, defensive strategies, like strict patient selection in certain
centers, could emerge. This emphasizes that TO should always be
used in addition to the other quality indicators.
Nevertheless, TO is a promising multidimensional indicator. It
reflects quality better than a single indicator and is suitable to guide
quality improvement. Although it remains difficult to predict TO
preoperatively, it may offer a powerful parameter to assess
between-hospital variation and to compare qualitybetween institutions
or audits. In other surgical audits in the Netherlands, TO has already
been successfully implemented as quality indicator for internal audit-
ing purposes. Hospitals are able to see their casemix-adjusted TO rate
in relation to the TO rates of other institutions, which might lead to an
intrinsic drive for quality assurance.
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